Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1975 2
1977 2
1978 3
1981 1
1982 1
1983 2
1986 1
1988 2
1991 2
1992 1
1993 1
1994 1
1996 1
1997 1
1999 2
2000 1
2001 1
2005 1
2008 3
2009 2
2010 8
2011 6
2012 11
2013 12
2014 7
2015 11
2016 3
2017 6
2018 10
2019 6
2020 14
2021 14
2022 14
2023 10
2024 20

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

162 results

Results by year

Filters applied: . Clear all
Page 1
A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody.
Koyama T, Kiyota N, Boku S, Imamura Y, Shibata N, Satake H, Tanaka K, Hayashi H, Onoe T, Asada Y, Yamazaki T, Nose T, Ohata S, Nagatani Y, Kimbara S, Funakoshi Y, Teshima M, Shinomiya H, Minami H. Koyama T, et al. Among authors: boku s. ESMO Open. 2024 Jun;9(6):103476. doi: 10.1016/j.esmoop.2024.103476. Epub 2024 Jun 3. ESMO Open. 2024. PMID: 38833968 Free PMC article. Clinical Trial.
The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine.
Hashimoto T, Nakamura Y, Fujisawa T, Imai M, Shibuki T, Iida N, Ozaki H, Nonomura N, Morizane C, Iwata H, Okano S, Yamagami W, Yamazaki N, Kadowaki S, Taniguchi H, Ueno M, Boku S, Oki E, Komatsu Y, Yuki S, Makiyama A, Otsuka T, Hara H, Okano N, Nishina T, Sakamoto Y, Miki I, Kobayashi S, Yuda J, Kageyama SI, Nagamine M, Sakashita S, Sakamoto N, Yamashita R, Koga Y, Bando H, Ishii G, Kuwata T, Park WY, Ohtsu A, Yoshino T. Hashimoto T, et al. Among authors: boku s. Cancer Discov. 2024 Nov 1;14(11):2243-2261. doi: 10.1158/2159-8290.CD-24-0206. Cancer Discov. 2024. PMID: 39023403 Free PMC article.
Clinical Validation of Plasma-Based Genotyping for RAS and BRAF V600E Mutation in Metastatic Colorectal Cancer: SCRUM-Japan GOZILA Substudy.
Aoki Y, Nakamura Y, Denda T, Ohta T, Esaki T, Shiozawa M, Yamaguchi K, Yamazaki K, Sunakawa Y, Kato T, Okano N, Taniguchi H, Sato T, Oki E, Nishina T, Komatsu Y, Matsuhashi N, Goto M, Yasui H, Ohtsubo K, Moriwaki T, Takahashi N, Horita Y, Boku S, Wakabayashi M, Ikeno T, Mitani R, Yuasa M, Yoshino T. Aoki Y, et al. Among authors: boku s. JCO Precis Oncol. 2023 Jun;7:e2200688. doi: 10.1200/PO.22.00688. JCO Precis Oncol. 2023. PMID: 37343204 Free PMC article.
Practice Guidelines for Bipolar Disorder by the JSMD (Japanese Society of Mood Disorders).
Kato T, Ogasawara K, Motomura K, Kato M, Tanaka T, Takaesu Y, Nio S, Kishi T, So M, Nemoto K, Suzuki E, Watanabe K, Matsuo K; JSMD Bipolar Disorder Guidelines Revision Working Group; JSMD Bipolar Disorder Committee; JSMD Guidelines Committee. Kato T, et al. Psychiatry Clin Neurosci. 2024 Nov;78(11):633-645. doi: 10.1111/pcn.13724. Epub 2024 Aug 28. Psychiatry Clin Neurosci. 2024. PMID: 39194164
Gut microbiome associated with PARP inhibitor efficacy in patients with ovarian cancer.
Okazawa-Sakai M, Sakai SA, Hyodo I, Horasawa S, Sawada K, Fujisawa T, Yamamoto Y, Boku S, Hayasaki Y, Isobe M, Shintani D, Hasegawa K, Egawa-Takata T, Ito K, Ihira K, Watari H, Takehara K, Yagi H, Kato K, Chiyoda T, Harano K, Nakamura Y, Yamashita R, Yoshino T, Aoki D. Okazawa-Sakai M, et al. Among authors: boku s. J Gynecol Oncol. 2024 Oct 21. doi: 10.3802/jgo.2025.36.e38. Online ahead of print. J Gynecol Oncol. 2024. PMID: 39453391 Free article.
Additional statin treatment enhances the efficacy of HER2 blockade and improves prognosis in Rac1-high/HER2-positive breast cancer.
Kato C, Iizuka-Ohashi M, Honda M, Konishi E, Yokota I, Boku S, Mizuta N, Morita M, Sakaguchi K, Taguchi T, Watanabe M, Naoi Y. Kato C, et al. Among authors: boku s. Biochim Biophys Acta Mol Basis Dis. 2024 Dec;1870(8):167458. doi: 10.1016/j.bbadis.2024.167458. Epub 2024 Aug 10. Biochim Biophys Acta Mol Basis Dis. 2024. PMID: 39128642 Free article.
Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody-Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer.
Iida N, Imai M, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y, Yuki S, Masuishi T, Nishina T, Ebi H, Taniguchi H, Nonomura N, Sunakawa Y, Shiozawa M, Yamazaki K, Boku S, Bando H, Shiraishi Y, Kobayashi M, Goto H, Sato A, Fujii S, Yoshino T, Nakamura Y. Iida N, et al. Among authors: boku s. Clin Cancer Res. 2024 Sep 13;30(18):4167-4178. doi: 10.1158/1078-0432.CCR-24-1023. Clin Cancer Res. 2024. PMID: 39163021 Free PMC article.
Safety of immune checkpoint inhibitors in patients aged over 80 years: a retrospective cohort study.
Ikoma T, Matsumoto T, Boku S, Motoki Y, Kinoshita H, Kosaka H, Kaibori M, Inoue K, Sekimoto M, Fujisawa T, Iwai H, Naganuma M, Tanizaki H, Hisamatsu Y, Okada H, Kurata T. Ikoma T, et al. Among authors: boku s. Cancer Immunol Immunother. 2024 May 11;73(7):126. doi: 10.1007/s00262-024-03707-4. Cancer Immunol Immunother. 2024. PMID: 38733406 Free PMC article.
162 results